Bernstein Harold sold $42K of MAZE
Bernstein Harold (President, R&D & CMO) sold 1,600 shares of Maze Therapeutics, Inc. (MAZE) at $26.36 on 2026-06-01 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure updates the insider activity record but does not introduce new clinical, regulatory, or financial information.
Market read
Traders may briefly reassess sentiment around MAZE based on insider activity, but the 10b5-1 structure typically limits signal strength.
What to watch
The filing doesn’t reveal reasons for sale, tax planning, or diversification; size is modest and post-transaction holdings are zero, but that alone isn’t proof of negative outlook.
Background
This is an SEC Form 4 insider transaction disclosure for Maze Therapeutics, Inc.
Ticker impact
SEC Form 4 shows MAZE President of R&D & CMO sold 1,600 shares in an open-market transaction under a 10b5-1 plan.
Limited near-term impact; any reaction is likely muted and short-lived.
The filing provides a specific sale price/date/size, but the transaction is explicitly under a pre-arranged Rule 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.
Market effects
Minimal; single-company insider transaction with no stated operational/regulatory catalyst.
None indicated.
None indicated.
Counterpoint
Even with 10b5-1, repeated insider selling can coincide with perceived risk; traders may watch for follow-on sales or lack of buys.
Key entities
- issuerMaze Therapeutics, Inc.
Subject of the Form 4 insider sale by its President, R&D & CMO.
- insiderHarold Bernstein
Officer (President, R&D & CMO) who sold shares under a Rule 10b5-1 plan.